These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36756387)

  • 41. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
    Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
    Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
    Vuong HG; Dunn IF
    J Neurooncol; 2022 Aug; 159(1):195-200. PubMed ID: 35768633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.
    Cheng CD; Chen C; Wang L; Dong YF; Yang Y; Chen YN; Niu WX; Wang WC; Liu QS; Niu CS
    Anal Cell Pathol (Amst); 2022; 2022():2376288. PubMed ID: 35757013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma.
    Jimenez C; Powers M; Parsa AT; Glastonbury C; Hagenkord JM; Tihan T
    J Neurooncol; 2011 Nov; 105(2):317-23. PubMed ID: 21533839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary cerebral gliosarcoma: report of 17 cases.
    Parekh HC; O'Donovan DG; Sharma RR; Keogh AJ
    Br J Neurosurg; 1995 Apr; 9(2):171-8. PubMed ID: 7632363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gliosarcoma case report and review of the literature.
    Awadalla AS; Al Essa AM; Al Ahmadi HH; Al Ojan A; Muazen Y; Alsayyah A; Alsaif H; Alsafwani NS
    Pan Afr Med J; 2020; 35():26. PubMed ID: 32341747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Competing Risk Model to Determine the Prognostic Factors for Patients with Gliosarcoma.
    Chen M; Huang L; Wang F; Xu X; Xu X
    World Neurosurg; 2024 Mar; 183():e483-e494. PubMed ID: 38157982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
    Huang Q; Li F; Chen Y; Hong F; Wang H; Chen J
    Br J Neurosurg; 2020 Apr; 34(2):161-167. PubMed ID: 31829033
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases].
    Huo Z; Liang Z; Li Y; Shen J; Bi Y; Meng Y; Zhang S; Luo Y; Cao J; Yang D
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):657-62. PubMed ID: 25567590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gliosarcoma with liposarcomatous differentiation: the new member of the lipid-containing brain tumors family.
    Vlodavsky E; Konstantinesku M; Soustiel JF
    Arch Pathol Lab Med; 2006 Mar; 130(3):381-4. PubMed ID: 16519569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
    Faustino AC; Viani GA; Hamamura AC
    Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
    Ogura K; Mizowaki T; Arakawa Y; Ogura M; Sakanaka K; Miyamoto S; Hiraoka M
    Radiat Oncol; 2013 Apr; 8():97. PubMed ID: 24499582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and survival characteristics of primary and secondary gliosarcoma patients.
    Amer A; Khose S; Alhasan H; Pokhylevych H; Fuller G; Chasen N; de Groot J; Johnson JM
    Clin Neurol Neurosurg; 2022 Mar; 214():107146. PubMed ID: 35101778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.